GL1X · GenesisL1 explorer

MolNFT v1 · #89803 · protein

Anophelin from the malaria vector inhibits thrombin through a novel reverse-binding mechanism

4E05: “Anophelin from the malaria vector inhibits thrombin through a novel reverse-binding mechanism”. X-ray diffraction, 2 ligands (NAG, NA), 3 pockets (best druggability 0.42). MolNFT v1 #89803 on GenesisL1: 3D structure, binding sites…

PDB
4E05
Type
protein
Length
312 residues
Chains
3
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Thrombin; Salivary anti-thrombin peptide anophelin
EC
3.4.21.5
UniProt
P00734, Q9NJS1
Ligands
NAG, NA
Pockets
3 · best druggability 0.42

Structure

x-ray diffraction · 3 distinct chains · 18% helix, 29% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
LThrombin (EC 3.4.21.5)protein2941% helix, 0% strandP00734
HThrombin (EC 3.4.21.5)protein25315% helix, 35% strandP00734
ISalivary anti-thrombin peptide anophelinprotein3020% helix, 7% strandQ9NJS1

Ligands and binding sites

  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · sugar · chains H
  • NA · Sodium ion · metal · chains H

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
1890.420.7814empty
21000.400.7616empty
3680.320.7516empty

Interfaces

2 interfaces between chains.

  • H–I · 1486 Ų buried · 28 hydrogen bonds · protein-protein
  • L–H · 1150 Ų buried · 28 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 4 disulfide, 1 glycan (disulfide, N-glycosylation).

Compared structures

  • 4E05 · Anophelin from the malaria vector inhibits thrombin through a novel reverse-binding… · the same entry in another collection · chain L against L, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.